A recombinant measles virus vaccine strain rMV-Hu191 has oncolytic effect against human gastric cancer by inducing apoptotic cell death requiring integrity of lipid raft microdomains

Lv, Yao; Zhou, Duo; Hao, Xiaoqiang; Zhu, Man; Zhang, Chu-di; Zhou, Dongming; Jin-hu, Wang; Liu, Rong-xian; Wang, Yilong; Gu, Weizhong; Shen, Hongqiang; Chen, Xi; Zhao, Zhengyan

doi:10.1016/j.canlet.2019.06.010

Cited by 16 publications

(9 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apoptosis, one type of cell death models, is mainly regulated by intrinsic, extrinsic apoptotic pathways and proapoptotic lipid signaling pathways [24,25]. We have previously shown that rMV-Hu191 alone could induce apoptotic cell death requiring integrity of lipid raft microdomains in human gastric cancer [22]. The present study further explores the role of lipid rafts in rMV-Hu191-induced apoptosis.…”

Section: Introductionmentioning

confidence: 62%

“…The lipid raft fractions were separated as previously described [22]. Briefly, GC cells after desired treatments were incubated with ice-cold solubilization buffer.…”

Section: Disruption and Isolation Of Cholesterol-rich 'Lipid Rafts'mentioning

confidence: 99%

“…Recently in our laboratory, rMV-Hu191, a recombinant Hu191 strain of measles virus has been successfully established [21]. It has been found in previous studies that rMV-Hu191 alone could be used as a potentially effective therapeutic agent in gastric cancer and colorectal cancer treatment [22,23]. Whether the rMV-Hu191 could synergize with DDP in GC is not reported to the date.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Synergism of rMV-Hu191 with cisplatin to treat gastric cancer by acid sphingomyelinase-mediated apoptosis requiring integrity of lipid raft microdomains

Zhang

Wang

et al. 2021

Gastric Cancer

Self Cite

View full text Add to dashboard Cite

Background DDP-based chemotherapy is one of the first-line treatment in GC. However, the therapeutic efficacy of DDP is limited due to side effects. Therefore, it is of great significance to develop novel adjuvants to synergize with DDP. We had demonstrated previously that rMV-Hu191 had antitumor activity in GC. Here we examined the synergism of rMV-Hu191 with DDP in vitro and in vivo. Methods Cellular proliferation, the synergistic effect and cell apoptosis were evaluated by CCK-8 assay, ZIP analysis and flow cytometry, respectively. The protein levels and location of ASMase were monitored by western blot and immunofluorescence assay. shRNA and imipramine were used to regulate the expression and activity of ASMase. MβCD was administrated to disrupt lipid rafts. Mice bearing GC xenografts were used to confirm the synergism in vivo. Results From our data, combinational therapy demonstrated synergistic cytotoxicity both in resistant GC cell lines from a Chinese patient and drug-nonresistant GC cell lines, and increased cell apoptosis, instead of viral replication. Integrity of lipid rafts and ASMase were required for rMV-Hu191- and combination-induced apoptosis. The ASMase was delivered to the lipid raft microdomains at the initial stage of rMV-Hu191 treatment. In vivo GC mice xenografts confirmed the synergism of combinational treatment, together with increased apoptosis and trivial side-effects. Conclusions This is the first study to demonstrate that rMV-Hu191 combined with DDP could be used as a potential therapeutic strategy in GC treatment and the ASMase and the integrity of lipid rafts are required for the synergistic effects.

show abstract

Section: Introductionmentioning

confidence: 62%

“…The lipid raft fractions were separated as previously described [22]. Briefly, GC cells after desired treatments were incubated with ice-cold solubilization buffer.…”

Section: Disruption and Isolation Of Cholesterol-rich 'Lipid Rafts'mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Synergism of rMV-Hu191 with cisplatin to treat gastric cancer by acid sphingomyelinase-mediated apoptosis requiring integrity of lipid raft microdomains

Zhang

Wang

et al. 2021

Gastric Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Gastric cancer is one of the most common malignancy that threaten the health of human beings, and the human gastric cancer SGC-7901 cell line is widely used in anti-tumoral studies in cellular level and on xenografted mouse model ( Lv et al, 2019 ). This kind of tumor is largely explored in clinical trial by anti-angiogenic approach, including anti-VEGF, which have shown some benefits in second line treatment ( Park et al, 2015 ).…”

Section: Resultsmentioning

confidence: 99%

A Cyclic Peptide Epitope of an Under-Explored VEGF-B Loop 1 Demonstrated In Vivo Anti-Angiogenic and Anti-Tumor Activities

Wang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Pathological angiogenesis is mainly initiated by the binding of abnormal expressed vascular endothelial growth factors (VEGFs) to their receptors (VEGFRs). Blocking the VEGF/VEGFR interaction is a clinically proven treatment in cancer. Our previous work by epitope scan had identified cyclic peptides, mimicking the loop 1 of VEGF-A, VEGF-B and placental growth factor (PlGF), inhibited effectively the VEGF/VEGFR interaction in ELISA. We described here the docking study of these peptides on VEGFR1 to identify their binding sites. The cellular anti-angiogenic activities were examined by inhibition of VEGF-A induced cell proliferation, migration and tube formation in human umbilical vein endothelial cells (HUVECs). The ability of these peptides to inhibit MAPK/ERK1/2 signaling pathway was examined as well. On chick embryo chorioallantoic membrane (CAM) model, a cyclic peptide named B-cL1 with most potent in vitro activity showed important in vivo anti-angiogenic effect. Finally, B-cL1 inhibited VEGF induced human gastric cancer SGC-7901 cells proliferation. It showed anti-tumoral effect on SGC-7901 xenografted BALB/c nude mouse model. The cyclic peptides B-cL1 constitutes an anti-angiogenic peptide drug lead for the design of new and more potent VEGFR antagonists in the treatment of angiogenesis related diseases.

show abstract

“…The infected tumor cells fuse into multinucleated syncytia, lose the integrity of the cell membrane, and eventually lead to cell death. MV replication, protein expression, syncytium formation and oncolytic effects have been verified in several human-derived cancer animal models, including circulatory system cancer such as leukemia [ 63 ] and myeloma [ 64 ], as well as solids tumors such as ovarian carcinoma [ 65 ], glioblastoma [ 66 ], liver cancer [ 67 ], pancreatic cancer [ 68 ], breast cancer [ 69 ] and gastric cancer [ 70 ].…”

Section: Types and Characteristics Of Ovsmentioning

confidence: 99%

Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical

Tang

et al. 2022

Clin Transl Oncol

View full text Add to dashboard Cite

With the in-depth research and wide application of immunotherapy recently, new therapies based on oncolytic viruses are expected to create new prospects for cancer treatment via eliminating the suppression of the immune system by tumors. Currently, an increasing number of viruses are developed and engineered, and various virus vectors based on effectively stimulating human immune system to kill tumor cells have been approved for clinical treatment. Although the virus can retard the proliferation of tumor cells, the choice of oncolytic viruses in biological cancer therapy is equally critical given their therapeutic efficacy, safety and adverse effects. Moreover, previously known oncolytic viruses have not been systematically classified. Therefore, in this review, we summarized and distinguished the characteristics of several common types of oncolytic viruses: herpes simplex virus, adenovirus, measles virus, Newcastle disease virus, reovirus and respiratory syncytial virus. Subsequently, we outlined that these oncolytic viral vectors have been transformed from preclinical studies in combination with immunotherapy, radiotherapy, chemotherapy, and nanoparticles into clinical therapeutic strategies for various advanced solid malignancies or circulatory system cancers.

show abstract

A recombinant measles virus vaccine strain rMV-Hu191 has oncolytic effect against human gastric cancer by inducing apoptotic cell death requiring integrity of lipid raft microdomains

Cited by 16 publications

References 46 publications

Synergism of rMV-Hu191 with cisplatin to treat gastric cancer by acid sphingomyelinase-mediated apoptosis requiring integrity of lipid raft microdomains

Synergism of rMV-Hu191 with cisplatin to treat gastric cancer by acid sphingomyelinase-mediated apoptosis requiring integrity of lipid raft microdomains

A Cyclic Peptide Epitope of an Under-Explored VEGF-B Loop 1 Demonstrated In Vivo Anti-Angiogenic and Anti-Tumor Activities

Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical

Contact Info

Product

Resources

About